Related Experiment Video
Updated: Mar 14, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey
Andrea Camerini1, Antonio Chella2, Francesca Mazzoni3
1a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Background:
We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population.
Patients And Methods:
We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany.
Results:
We evaluated 62 (median age: 63.5 [30-77] years) pts. All but one presented with adenocarcinoma and the majority had ECOG PS of 0/1. 17.7% presented with central lesion, 11.3% with brain metastasis, 38.7% with hypertension and 4.8% with mild haemoptysis. We observed a median time to progression (TTP) of 6.5 [2-37] and a median overall survival (OS) of 10.5 [2-39] months. Overall response rate (ORR) was 59.6% with a disease control rate (DCR) of 80.6%. Safety profile was acceptable. We observed five cardiovascular events and two major bleedings with no toxic deaths.
Conclusion:
Safety and efficacy real world data are consistent with those from clinical trials even in a less selected population.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
